IMU Biosciences

IMU Biosciences develops an immune profiling platform it calls HD Immunology. The company states that it measures over 100 million data points from a single 2 ml blood sample and resolves 2,500 immune cell subsets. Its programmes cover a predictive screening tool for graft efficacy in hematopoietic stem cell transplantation, tools predicting graft rejection in solid organ transplantation, and predictive signatures for checkpoint inhibition in immuno-oncology.

According to its website, IMU works with clinical research groups, pharma, biotech and diagnostics companies to support drug discovery and development and precision medicine. Announced partnerships include Eurofins Transplant Genomics and Waters Corporation. The website does not describe the revenue model.

IMU states that it was founded on decades of research and has completed a $53 million Series A. The team is described as immunologists, computational biologists, data scientists and engineers. The careers page lists hybrid, full-time openings in London, including Communications and Marketing Manager and Bioinformatics Software Engineer roles.

Product: HD Immunology multi-omic immune profiling platform that resolves 2,500 immune cell subsets from 2 ml of blood, with programmes in HSCT, SOT and immuno-oncology.